Innate Pharma SA
F:IDDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innate Pharma SA
F:IDDA
|
FR |
|
R
|
Raymond James Financial Inc
F:RJF
|
US |
|
Pharnext SA
PAR:ALPHA
|
FR |
|
L
|
Lincoln National Corp
DUS:LCO
|
US |
|
P
|
Postal Realty Trust Inc
F:2WP
|
US |
|
R
|
R&B Food Supply PCL
SET:RBF
|
TH |
|
N
|
Nov Inc
XMUN:NO8
|
US |
Wall St Price Targets
IDDA Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for IDDA is 4.92 EUR with a low forecast of 4.1 EUR and a high forecast of 5.87 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IDDA's stock price target?
Price Target
4.92
EUR
According to Wall Street analysts, the average 1-year price target for IDDA is 4.92 EUR with a low forecast of 4.1 EUR and a high forecast of 5.87 EUR.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
1 086%
The compound annual growth rate for Gross Profit over the next 3 years is 1 086%.
